Scarica l'app Stockscreener
78.35
2.65%
2.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CVS Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$76.33
Aprire:
$76.37
Volume 24 ore:
7.08M
Relative Volume:
0.88
Capitalizzazione di mercato:
$99.46B
Reddito:
$393.94B
Utile/perdita netta:
$428.00M
Rapporto P/E:
204.78
EPS:
0.3826
Flusso di cassa netto:
$6.29B
1 W Prestazione:
+5.14%
1M Prestazione:
-2.91%
6M Prestazione:
+23.35%
1 anno Prestazione:
+44.45%
Intervallo 1D:
$76.19
$78.96
Intervallo di 1 settimana:
$73.40
$78.96
Portata 52W:
$53.36
$85.15
Cvs Health Corp Stock (CVS) Company Profile
Nome
Cvs Health Corp
Settore
Industria
Telefono
(401) 765-1500
Indirizzo
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, CI, ELV, HUM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
78.35 | 96.90B | 393.94B | 428.00M | 6.29B | 0.3826 |
|
UNH
Unitedhealth Group Inc
|
276.65 | 243.26B | 447.57B | 12.81B | 16.08B | 13.19 |
|
CI
Cigna Group
|
292.05 | 74.96B | 216.66B | 6.25B | 7.44B | 22.19 |
|
ELV
Elevance Health Inc
|
338.98 | 73.84B | 199.13B | 5.66B | 3.17B | 25.11 |
|
HUM
Humana Inc
|
193.94 | 23.28B | 126.36B | 1.30B | 1.55B | 10.67 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Iniziato | Goldman | Buy |
| 2025-08-18 | Aggiornamento | UBS | Neutral → Buy |
| 2025-08-14 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Edward Jones | Hold → Buy |
| 2024-12-03 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-30 | Iniziato | Robert W. Baird | Neutral |
| 2024-05-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-05-02 | Downgrade | UBS | Buy → Neutral |
| 2024-05-01 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Iniziato | Barclays | Equal Weight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2023-12-22 | Iniziato | HSBC Securities | Buy |
| 2023-09-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Downgrade | Edward Jones | Buy → Hold |
| 2023-05-26 | Iniziato | Piper Sandler | Overweight |
| 2023-04-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Ripresa | Morgan Stanley | Overweight |
| 2022-06-17 | Iniziato | Loop Capital | Buy |
| 2022-05-27 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Iniziato | Goldman | Buy |
| 2021-12-01 | Iniziato | Seaport Research Partners | Buy |
| 2021-05-19 | Iniziato | Wells Fargo | Equal Weight |
| 2021-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-01-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-17 | Iniziato | Piper Sandler | Overweight |
| 2020-07-01 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-05-14 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Ripresa | RBC Capital Mkts | Outperform |
| 2019-09-12 | Iniziato | Deutsche Bank | Buy |
| 2019-06-05 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2019-04-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Iniziato | Guggenheim | Buy |
| 2019-04-15 | Downgrade | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Reiterato | BofA/Merrill | Buy |
| 2019-03-13 | Iniziato | Bernstein | Outperform |
| 2019-02-20 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Iniziato | UBS | Buy |
| 2018-12-18 | Iniziato | Barclays | Overweight |
| 2018-11-29 | Ripresa | Goldman | Neutral |
| 2018-11-28 | Iniziato | Evercore ISI | Outperform |
| 2018-10-26 | Ripresa | Wolfe Research | Peer Perform |
| 2018-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-02-27 | Ripresa | BofA/Merrill | Buy |
| 2018-02-13 | Reiterato | Citigroup | Neutral |
Mostra tutto
Cvs Health Corp Borsa (CVS) Ultime notizie
CVS Health Stock at a Crossroads: Value Trap or Quiet Turnaround Story? - AD HOC NEWS
Should You Buy CVS Health Stock Before Feb. 10? - The Motley Fool
CVS (CVS) Accepts TrumpRx Discount Cards for Prescription Drugs - GuruFocus
CVS Health (CVS) Embraces TrumpRx Discount Cards for Medication Savings - GuruFocus
CVS Pharmacy now accepting TrumpRx discount cards - Investing.com
TrumpRx drug discounts now available at 9,000 CVS pharmacies - stocktitan.net
CVS Expands Biosimilar Access to Lower Drug Costs - intellectia.ai
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
CVS Specialty brings empathy and expertise to fertility patients - CVS Health
A Look Into CVS Health Inc's Price Over Earnings - Benzinga
CVS Faces Medicaid Network Loss And PBM Scrutiny As Valuation Looks Undemanding - simplywall.st
Aetna, a CVS Health company, receives Health Plan of the Year Award from Press Ganey - CVS Health
Why Press Ganey named Aetna its first Health Plan of the Year - stocktitan.net
CVS Health (CVS) Expands Biosimilar Offerings to Cut Costs - GuruFocus
CVS Health to swap Amgen and Lilly’s bone drugs with biosimilars in commercial formularies - Seeking Alpha
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists - Reuters
Is CVS Health Stock a Bad-News Buy? - AOL.com
UnitedHealth, CVS, Humana Face Double Trouble As Trump's Medicare Cuts Are Just The Start—PBM 'Spread Pricing' Comes Under Fire - Yahoo Finance
New CVS drug list swaps Prolia for cheaper osteoporosis shots - stocktitan.net
Aetna launches simplified, digital-first, benefits onboarding experience for members in 2026 - CVS Health
How Aetna’s new texting tools boosted member engagement 80%+ - stocktitan.net
CVS Health (CVS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance Australia
Cigna settles FTC insulin case, aims to lower drug prices - WTAQ
Express Scripts Reaches Deal With FTC Over Insulin Pricing Practices - PYMNTS.com
Cigna settles FTC insulin case, commits to overhauling drug pricing - CNBC
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
UNH Stock: The Factors Behind UnitedHealth's Struggles in Its Recovery - intellectia.ai
Exclusive: Cigna settles FTC insulin case, aims to lower drug prices - Reuters
Four drugs to watch in 2026 that could reshape treatment options - CVS Health
Wegmans, CVS add SNAP/EBT payments on DoorDash - NJBIZ
Exclusive-Cigna settles FTC insulin case, commits to overhauling drug pricing - Bitget
CVS Health: Exploit The Sector Panic Ahead Of Earnings (NYSE:CVS) - Seeking Alpha
CVS Health (CVS) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
CVS Health’s (CVS) Path Forward: Policy Challenges, Analyst Views, and Dividend Stability - Insider Monkey
CVS Health's (CVS) Path Forward: Policy Challenges, Analyst Views, and Dividend Stability - Finviz
CVS Pharmacy: How America’s Most Convenient Drugstore Quietly Became a Daily-Life Lifesaver - AD HOC NEWS
Shorts Report: How does CVS Health Corporation correlate with Nasdaq2025 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
CVS Health Corporation (CVS) Positioned for Long-Term Growth Amid Policy Shifts - Finviz
CVS Health Faces Antitrust Scrutiny As Valuation Flags Undervaluation Risk - Yahoo Finance UK
Argus Trims CVS Health (CVS) PT to $90 Amid Medicare Advantage Rate Uncertainty - Finviz
National Pension Service Purchases 119,189 Shares of CVS Health Corporation $CVS - MarketBeat
Looking Into CVS Health Corp's Recent Short Interest - Benzinga
AustralianSuper Pty Ltd Sells 492,309 Shares of CVS Health Corporation $CVS - MarketBeat
AE Wealth Management LLC Has $19.39 Million Stock Position in CVS Health Corporation $CVS - MarketBeat
US Labor Department proposes rule to boost transparency in pharmacy benefit manager fees - AOL.com
CVS Health Corporation $CVS Shares Sold by New York State Common Retirement Fund - MarketBeat
Novare Capital Management LLC Has $398,000 Stake in CVS Health Corporation $CVS - MarketBeat
CVS Health Corporation $CVS Shares Sold by Bank of New York Mellon Corp - MarketBeat
CVS Health and Merck Stocks Undervalued, 2026 Revenue Guidance of $400 Billion - Intellectia AI
CVS Health Corporation (NYSE:CVS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
CVS Pharmacy Review 2026: Why This Everyday Drugstore Is Quietly Becoming a Health Hub - AD HOC NEWS
Cvs Health Corp Azioni (CVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):